KalVista (NASDAQ: KALV) posts $35M quarter, $49M over 8-month period

Rhea-AI Filing Summary

KalVista Pharmaceuticals reported preliminary global net revenue of approximately $35 million for the quarter and $49 million for the eight‑month transition period ended December 31, 2025. These figures are early estimates and rely on the company’s financial closing procedures and the completion of an audit of its financial statements for that transition period. The company emphasized that the final audited results could differ materially from these preliminary numbers. KalVista also released a press release and an updated corporate presentation, which are attached as exhibits to this report.

Insights

Biopharma equity analyst

KalVista shares early revenue estimates that remain subject to audit and potential revision.

KalVista Pharmaceuticals disclosed preliminary global net revenue of about $35 million for the quarter and $49 million for the eight‑month transition period ended December 31, 2025. This offers an early view of commercial performance during a nonstandard, eight‑month reporting stretch, which can reflect changes in fiscal year timing or reporting alignment.

The company clearly states that these numbers are estimates pending completion of financial closing procedures and an audit of the transition period financial statements. Because the audited results may differ materially, any interpretation of trends or profitability based solely on these figures carries uncertainty. Subsequent audited financial statements for the period ended December 31, 2025 will provide the definitive financial picture.

false 0001348911 0001348911 2026-01-08 2026-01-08

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 8, 2026

KALVISTA PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware		001-36830		20-0915291
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

200 Crossing Boulevard

Framingham, Massachusetts 01702

(Address of Principal Executive Offices) (Zip Code)

(857) 999-0075

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 Par Value Per Share		KALV		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On January 8, 2026, KalVista Pharmaceuticals, Inc. (the “Company”) issued a press release (the “Press Release”) announcing preliminary global net revenue of approximately $35 million and $49 million for the quarter and the eight month transition period ended December 31, 2025, respectively.

The Company’s audited financial statements for the eight month transition period ended December 31, 2025, are not yet available. Accordingly, the preliminary financial information included in the Press Release is an estimate subject to the completion of the Company’s financial closing procedures and any adjustments that may result from the completion of the audit of the Company’s financial statements. The preliminary financial information may differ materially from the actual results that will be reflected in the Company’s audited financial statements when they are completed and publicly disclosed.

Item 7.01. Regulation FD Disclosure.

On January 8, 2026, the Company issued the Press Release and updated corporate presentation. Copies of the Press Release and corporate presentation issued by the Company are furnished as Exhibits 99.1 and 99.2, respectively, to this report.

The information furnished with Item 2.02 and Item 7.01 of this report, including Exhibits 99.1 and 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description of Exhibit
99.1		Press Release issued January 8, 2026.
99.2		Corporate Presentation.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				KALVISTA PHARMACEUTICALS, INC.
Date: January 8, 2026				By:		/s/ Brian Piekos
						Brian Piekos
						Chief Financial Officer

FAQ

What preliminary revenue did KalVista (KALV) report for the latest quarter?

KalVista reported preliminary global net revenue of approximately $35 million for the quarter ended December 31, 2025, based on its initial closing procedures.

What preliminary revenue did KalVista (KALV) report for the eight-month transition period?

For the eight‑month transition period ended December 31, 2025, KalVista reported preliminary global net revenue of about $49 million.

Are KalVista’s reported revenues final audited figures?

No. KalVista stated that these revenues are preliminary estimates and may differ materially from the audited financial statements once the audit is completed.

Why did KalVista file this 8-K related to revenue?

KalVista filed this report because it issued a press release announcing preliminary revenue for the quarter and eight‑month transition period ended December 31, 2025.

What exhibits did KalVista (KALV) include with this 8-K filing?

The filing includes a press release dated January 8, 2026 as Exhibit 99.1 and an updated corporate presentation as Exhibit 99.2.

Does this 8-K mean KalVista’s information is incorporated into other SEC filings?

The company specified that the information under Items 2.02 and 7.01, including Exhibits 99.1 and 99.2, is furnished, not filed, and is not incorporated into other filings unless specifically referenced.